Cvsi Plus CBD Oil

CBDISTILLERY

Buy CBD Oil Online

CVSciences is the #1 selling hemp extract in the USA with products including CBD gummies, CBD capsules, balms & more. Refreshed Website Guides Visitors on their Hemp CBD Journey with Multimedia Educational Resources, In-Depth Product Information and Improved Shopping… The market for products featuring hemp extracts is large and growing larger. However, safety concerns have been raised by medical and regulatory agencies. Post marketing surveillance of full spectrum hemp extract (FSHE) products manufactured and distributed by CV Sciences (CVSI) and traded under the …

Collection

Modern life is challenging. Our physical, mental, and emotional health is constantly being tested. We provide research based solutions for the well being of the planet. This is health transformed.

CBD SOFTGEL CAPSULES 50MG 60CT

CV Acute Intensive Immune Support (Non-CBD Formula)

CV Defense Daily Immune Support (Non-CBD Formula)

Happy Lane CBD Softgel Capsules 60ct 25mg 0.00% THC

CBD SOFTGEL CAPSULES 50MG 60CT

CV Acute Intensive Immune Support (Non-CBD Formula)

CV Defense Daily Immune Support (Non-CBD Formula)

Happy Lane CBD Softgel Capsules 60ct 25mg 0.00% THC

WHO ARE WE

We began as a small group believing in the power of plants. Our families and friends achieved astonishing results with our products — so we committed ourselves to an intrepid path of discovery to connect nature with science.

OUR CORE VALUES

So, who are we? It’s in our name. CV, or curriculum vitae, is Latin for “course of life”, and science is the pursuit of truth. CV Sciences: our name is our mission — improving quality of life through nature and science.

CLINICALLY RESEARCHED IMMUNE SUPPORT

We challenged our team of doctors and scientists to come up with products that will genuinely support people and their immune systems during these difficult times. They came back with clinically supported formulas that look to nature and lean into science.

CV Sciences, Inc. Launches Updated +PlusCBD™ Oil Website to Enhance User Experience and Drive Increased E-Commerce Sales

January 23, 2020 08:45 ET | Source: CV Sciences, Inc. CV Sciences, Inc.

See also  CBD Oil Chesapeake Va

San Diego, California, UNITED STATES

Refreshed Website Guides Visitors on their Hemp CBD Journey with Multimedia Educational Resources, In-Depth Product Information and Improved Shopping Tools

Company Well Positioned to Drive Rapid E-Commerce Channel Growth

SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the launch of its updated PlusCBD™ Oil website: www.pluscbdoil.com.

With a fresh look and feel, the updated PlusCBD™ Oil website offers visitors an enhanced user experience and walks them through their hemp CBD journey, with multimedia educational resources, enriched content, informative blog posts, groundbreaking research, in-depth product information and improved shopping tools, resulting in an easy-to-use customer experience. The updated website also offers an interactive quiz that recommends specific products to best suit a person’s unique needs and lifestyle.

“The refreshed PlusCBD™ Oil website is designed to add value to our new and existing customers throughout their entire CBD journey, from CBD education through product selection and checkout,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “During the past year, we have invested heavily in personnel, technology and digital marketing to support expansion of our direct-to-consumer e-commerce sales initiatives to ensure we are best positioned to drive growth through this important channel.”

Dowling continued, “E-commerce is our fastest growing channel, accounting for 21.6% of total sales in our most recently reported quarter, and we believe there is a significant growth opportunity for CV Sciences in e-commerce. We anticipate that the new PlusCBD™ Oil website will further enable CV Sciences to increase sales, enhance customer loyalty and capture greater market share in the hemp CBD category.”

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil products are sold at more than 5,700 retail locations through the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

See also  CBD Oil In Swansea

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
[email protected]

Post Marketing Safety of Plus CBD™ Products, a Full Spectrum Hemp Extract: A 2-Year Experience

The market for products featuring hemp extracts is large and growing larger. However, safety concerns have been raised by medical and regulatory agencies. Post marketing surveillance of full spectrum hemp extract (FSHE) products manufactured and distributed by CV Sciences (CVSI) and traded under the brand PlusCBD™ was conducted over a 2-year period (2018-2019). The safety of these products was assessed by analyzing adverse events reports. From a total of approximately five million product units sold during the 2-year period, 1,429 (0.03%) adverse events (AE) were reported in 1,151 unique customers. Of those, only two were classified as serious AEs. For orally ingested products, the most common types of AEs reported were gastrointestinal (e.g. abdominal discomfort), while for topically applied products, the most reports mentioned dermatological symptoms (e.g. rashes). There has been no evidence of liver toxicity associated with CVSI products. Based on this longitudinal dataset, the products manufactured using CVSI’s proprietary processes are safe and well tolerated at the recommended doses.

See also  CBD Oil For Dogs Gold Bee

Keywords: CBD; DSHEA; adverse event; cannabidiol; dietary supplement; full spectrum hemp extract (FSHE); nutravigilance; pharmacovigilance; serious adverse event; supplement safety.

Similar articles

Schmitz SM MD, MPH, Lopez HL MD, MS, Mackay D ND, Nguyen H BS, Miller PE BS. Schmitz SM MD, MPH, et al. J Diet Suppl. 2020;17(2):227-248. doi: 10.1080/19390211.2018.1513109. Epub 2018 Dec 4. J Diet Suppl. 2020. PMID: 30513022

Marinotti O, Sarill M. Marinotti O, et al. J Diet Suppl. 2020;17(5):517-526. doi: 10.1080/19390211.2020.1776806. Epub 2020 Jun 16. J Diet Suppl. 2020. PMID: 32543253

Cogan PS. Cogan PS. J Diet Suppl. 2020;17(5):527-542. doi: 10.1080/19390211.2020.1790710. Epub 2020 Jul 17. J Diet Suppl. 2020. PMID: 32677489

Clark JA, Humphries JE, Crean S, Reynolds MW. Clark JA, et al. Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874. Pharmacoepidemiol Drug Saf. 2010. PMID: 20014051 Review.

VanDolah HJ, Bauer BA, Mauck KF. VanDolah HJ, et al. Mayo Clin Proc. 2019 Sep;94(9):1840-1851. doi: 10.1016/j.mayocp.2019.01.003. Epub 2019 Aug 22. Mayo Clin Proc. 2019. PMID: 31447137 Review.

Cited by

Lachenmeier DW, Walch SG. Lachenmeier DW, et al. F1000Res. 2020 Aug 26;9:1051. doi: 10.12688/f1000research.26045.2. eCollection 2020. F1000Res. 2020. PMID: 33082934 Free PMC article.

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.